TOP > 外国特許検索 > ANTIBODY FOR SPECIFICALLY RECOGNIZING AND BINDING ACTIVE-STRUCTURE REIC/DKK-3 PROTEIN, AND MONITORING FOR CANCER TREATMENT IN WHICH SAID ANTI-REIC/DKK-3 ANTIBODY IS USED

ANTIBODY FOR SPECIFICALLY RECOGNIZING AND BINDING ACTIVE-STRUCTURE REIC/DKK-3 PROTEIN, AND MONITORING FOR CANCER TREATMENT IN WHICH SAID ANTI-REIC/DKK-3 ANTIBODY IS USED

外国特許コード F170009079
整理番号 (S2015-2066-N0)
掲載日 2017年5月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP078339
国際公開番号 WO 2017057308
国際出願日 平成28年9月27日(2016.9.27)
国際公開日 平成29年4月6日(2017.4.6)
優先権データ
  • 特願2015-190401 (2015.9.28) JP
発明の名称 (英語) ANTIBODY FOR SPECIFICALLY RECOGNIZING AND BINDING ACTIVE-STRUCTURE REIC/DKK-3 PROTEIN, AND MONITORING FOR CANCER TREATMENT IN WHICH SAID ANTI-REIC/DKK-3 ANTIBODY IS USED
発明の概要(英語) Provided is an anti-REIC antibody with which it is possible to specifically recognize a cancer-related protein REIC/Dkk-3 and to monitor the results of a cancer treatment in which a REIC/Dkk-3 gene or the REIC/Dkk-3 protein is used as a medicine. Also provided is a method for diagnosis in which said antibody is used. A method for detecting cancer in which: the concentration of REIC/Dkk-3 protein in a biological sample collected from a subject is measured using a first antibody, or a functional fragment thereof, that specifically recognizes a REIC/Dkk-3 protein produced by normal cells and having an active structure, but that does not bind REIC/Dkk-3 protein present in large quantities in the blood of a cancer patient without recognizing said REIC/Dkk-3 protein or has low reactivity with REIC/Dkk-3 protein present in large quantities in the blood of a cancer patient; and, when the concentration of REIC/Dkk-3 protein in the biological sample from the subject is lower than the concentration of REIC/Dkk-3 protein in a biological sample from a normal individual, an assessment is made that the subject is affected by precancer or a neoplastic disorder.
従来技術、競合技術の概要(英語) BACKGROUND ART
As the genes associated with immortalization of cells, are known and REIC/Dkk-3 gene, the expression of this gene in cancer cells can be suppressed has been reported (Patent Document 1 and non-patent document 1 4 from the reference).
Dkk family of genes REIC/Dkk-3 and, through the Wnt receptor inhibits Wnt signaling are (see Non-Patent Document 5 and 6), Wnt genes, cell growth, differentiation, such as canceration of the important biological state can serve multiple roles have been reported (see Non-Patent Document 5 and 7).
The full length protein at a concentration of 10μg/ml REIC/Dkk-3 peripheral blood mononuclear cells (monocytes) were cultured in the medium in which added, the same cells differentiate into dendritic cell-like cells have been reported (see Patent Document 2).
And the animal experiment, the entire length of the fragment peptide protein and REIC/Dkk-3, for administration to the mouse tumor model indicate significant tumor reduction effect has been reported (see Patent Document 3).
Further adaptation of the human, using an adenovirus gene therapy REIC/Dkk-3, metastatic castration-resistant prostate cancer patients with a (complete remission) cases have been reported (see Non-Patent Document 8).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
  • MOMOTARO-GENE INC.
  • 発明者(英語)
  • KUMON Hiromi
  • KINOSHITA Rie
  • FUTAMI Junichiro
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close